logo
Exclusive-Medical journal rejects Kennedy's call for retraction of vaccine study

Exclusive-Medical journal rejects Kennedy's call for retraction of vaccine study

Yahooa day ago
By Michael Erman and Jennifer Rigby
(Reuters) -An influential U.S. medical journal is rejecting a call from Health Secretary Robert F. Kennedy Jr. to retract a large Danish study that found that aluminum ingredients in vaccines do not increase health risks for children, the journal's editor told Reuters.
Kennedy has long promoted doubts about vaccines' safety and efficacy, and as health secretary has upended the federal government's process for recommending immunization. A recent media report said he has been considering whether to initiate a review of shots that contain aluminum, which he says are linked to autoimmune diseases and allergies.
The study, which was funded by the Danish government and published in July in the Annals of Internal Medicine, analyzed nationwide registry data for more than 1.2 million children over more than two decades. It did not find evidence that exposure to aluminum in vaccines had caused an increased risk for autoimmune, atopic or allergic, or neurodevelopmental disorders.
The work is by far the best available evidence on the question of the safety of aluminum in vaccines, said Adam Finn, a childhood vaccination expert in the UK and pediatrician at the University of Bristol, who was not involved in the study.
"It's solid, (a) massive dataset and high-quality data," he said.
Kennedy described the research as "a deceitful propaganda stunt by the pharmaceutical industry," and said the scientists who authored it had "meticulously designed it not to find harm" in a detailed Aug. 1 opinion piece on TrialSite News, an independent website focused on clinical research. He called on the journal to "immediately retract" the study.
"I see no reason for retraction," Dr. Christine Laine, editor in chief of the Annals and a professor of medicine at Thomas Jefferson University, said in an interview.
The journal plans to respond to criticism the article has received on its website, Laine said, but it does not intend to respond directly to Kennedy's piece, which was not submitted to the Annals.
The lead author of the study, Anders Peter Hviid, head of the epidemiology research department at the Statens Serum Institut in Denmark, defended the work in a response post to TrialSite. He wrote that none of the critiques put forward by Kennedy were substantive and he categorically denied any deceit as implied by the secretary.
"I am used to controversy around vaccine safety studies - especially those that relate to autism, but I have not been targeted by a political figurehead in this way before," Hviid said in an emailed response to Reuters. "I have confidence in our work and in our ability to reply to the critiques of our study."
Kennedy had a number of critiques, including the lack of a control group, that the study deliberately excluded different groups of children to avoid showing a link between aluminum and childhood health conditions - including those with the highest levels of exposure - and that it did not include the raw data.
Hviid responded to the criticisms on TrialSite. He said some of the points were related to study design choices that were reasonable to discuss but refuted others, including that the study was designed not to find a link. In fact he said, its design was based on a study led by Matthew Daley, a pediatrician at Kaiser Permanente Colorado, which did show a link, and which Kennedy cited in his article.
There was no control group because in Denmark, only 2% of children are unvaccinated, which is too small for meaningful comparison, Hviid added. The data is available for researchers to analyze, but individual-level data is not released under Danish law, he said.
Other prominent vaccine skeptics including those at the antivaccine organization Kennedy previously ran, Children's Health Defense, have similarly criticized the study on the Annals site.
TrialSite staff defended the study for its scale, data transparency and funding while acknowledging the limitations of its design, a view seconded by some outside scientists.
Laine said that while some of the issues Kennedy raised in his article may underscore acceptable limitations of the study, "they do not invalidate what they found, and there's no evidence of scientific misconduct."
An HHS spokesman said the department had "no further comment than what the secretary said."
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available

Yahoo

time28 minutes ago

  • Yahoo

Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available

The celebration marks a major milestone for the patent-pending, next-generation, rapid, compact, and hand-held Daxor BVA™. Oak Ridge, TN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces that the official replay of its Nasdaq Closing Bell Ceremony is now available. The ceremony, which took place on August 8, 2025, commemorated the FDA 510(k) clearance for its patent-pending, next-generation, rapid, compact, hand-held, lab-based new Daxor BVA™ (Blood Volume Analyzer). You can watch the full replay of the event here: Closing Ceremony. For more information, visit Sign up to receive news on Daxor's innovative technology HERE. About Daxor Corporation Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor's patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion. Forward-Looking Statements Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:Investor Relations Contact:Bret ShapiroCOO – Head of Capital MarketsCOREIR(561)-479-8566-Cellbrets@ in to access your portfolio

Here's Why Halozyme Therapeutics (HALO) Traded Town in Q2
Here's Why Halozyme Therapeutics (HALO) Traded Town in Q2

Yahoo

time28 minutes ago

  • Yahoo

Here's Why Halozyme Therapeutics (HALO) Traded Town in Q2

Meridian Funds, managed by ArrowMark Partners, released its 'Meridian Growth Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets made a significant rebound during the quarter, increasing 23% from intra-period lows to close at record highs. Against this backdrop, the fund returned 4.10% (net) compared to the Russell 2500 Growth Index's 11.31% return. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Meridian Growth Fund highlighted stocks such as Halozyme Therapeutics, Inc. (NASDAQ:HALO). Based in San Diego, California, Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company. The one-month return of Halozyme Therapeutics, Inc. (NASDAQ:HALO) was 11.11%, and its shares gained 12.32% of their value over the last 52 weeks. On August 11, 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock closed at $62.89 per share, with a market capitalization of $7.356 billion. Meridian Growth Fund stated the following regarding Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its second quarter 2025 investor letter: "Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous delivery of biologics and fluids, transforming hours-long intravenous (IV) infusions into quick injections that can be delivered in just minutes. By doing so, ENHANZE can significantly reduce the treatment burden for patients and ease capacity constraints for healthcare providers. Shares of Halozyme declined during the period following news that the Centers for Medicare & Medicaid Services (CMS) may reconsider how it classifies reformulated drugs using ENHANZE. Under the proposed change, such formulations may no longer qualify as 'new drugs,' potentially subjecting them to Medicare price negotiations earlier than previously expected. While the proposal remains under review, we believe ENHANZE continues to offer meaningful advantages—including fewer injection-site reactions and substantial time and cost savings for clinics—making it an important innovation in drug delivery. We slightly reduced our position in the company during the quarter." An image of a research technician wearing lab coat with a syringe full of biopharmaceuticals. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 31 hedge fund portfolios held Halozyme Therapeutics, Inc. (NASDAQ:HALO) at the end of the first quarter, which was 25 in the previous quarter. In the second quarter of 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported revenue of $326 million, representing 41% year-over-year increase. While we acknowledge the potential of Halozyme Therapeutics, Inc. (NASDAQ:HALO) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Halozyme Therapeutics, Inc. (NASDAQ:HALO) and shared the list of most undervalued biotech stocks to buy. Halozyme Therapeutics, Inc. (NASDAQ:HALO) rose in the previous quarter due to strong earnings and its decision to focus on its core business. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Mario and Courtney Lopez Team Up with NaturVet to Spotlight Award-Winning Pet Supplements at SuperZoo 2025
Mario and Courtney Lopez Team Up with NaturVet to Spotlight Award-Winning Pet Supplements at SuperZoo 2025

Yahoo

time28 minutes ago

  • Yahoo

Mario and Courtney Lopez Team Up with NaturVet to Spotlight Award-Winning Pet Supplements at SuperZoo 2025

The duo will showcase NaturVet's offerings, led by All-In-One Daily Care, recently named "Dog Vitamin/Supplement Innovation of the Year" LAS VEGAS, Aug. 12, 2025 /PRNewswire/ -- Mario and Courtney Lopez are joining NaturVet at SuperZoo 2025 to celebrate the brand's refreshed look and inspire pet parents to take a proactive approach to their pets' health and wellness. The show is August 13-15 at Mandalay Bay Convention Center, and the beloved television personalities will appear at booth #9747 on day two for a media/VIP event. "Having Mario and Courtney Lopez join us at SuperZoo is incredibly exciting," said Geoff Granger, CEO at NaturVet. "We share a passion for helping pets live healthier, happier lives, and their involvement allows us to extend this message to even more pet parents." NaturVet's All-In-One Daily Care line was recently named "Dog Vitamin/Supplement Innovation of the Year" by the 2025 Pet Innovation Awards, a prestigious program that recognizes the most innovative companies, services and products in the global pet industry. With comprehensive, vet-formulated benefits and easy-to-give soft chews, the All-In-One line stood out for delivering real results for dogs at every life stage, from puppyhood through their senior years. NaturVet will showcase its award-winning All-In-One Daily Care line at SuperZoo, along with a range of new product innovations including: All-In-One Puppy Daily Care: A soft chew supplement with a hickory smoked bacon flavor designed to support the needs of growing puppies with six essential key benefits, including skeletal support, brain development, healthy digestion and immune health. Formulated for younger dogs, it features the exclusive dental care ingredient PlaqueOff® for added oral health support. All-In-One Adult Daily Care: A 10-in-1 soft chew supplement designed to support adult dogs with targeted benefits, including joint health, digestion, immunity, skin and coat health and more. Featuring a delicious hickory smoked bacon flavor and the exclusive dental care ingredient PlaqueOff®, it helps support overall health and well-being throughout adulthood. All-In-One Senior Daily Care: An 8-in-1 soft chew supplement designed to support aging dogs by targeting areas such as joint health, mobility and gut health, while also providing brain, heart and vision support. It features the exclusive ingredient PlaqueOff® for dental care and tailored ingredients that help support longevity and immunity. With its hickory smoked bacon flavor, the soft chews are easy to give to senior dogs. Lickable Supplements for Cats: A pump-dispensed supplement designed for easy dosing. Available in Hip & Joint, Calming and Multi-Vitamin formulas, it provides essential support in a mess-free format, making supplementation effortless for cat owners. Lickable Supplements for Dogs: A peanut butter-flavored supplement for dogs, available in Hip & Joint, Calming and Multi-Vitamin formulas. Designed for easy dosing with a pump, it offers a convenient, mess-free alternative to traditional supplements while addressing key dog health and wellness needs. SuperZoo attendees are invited to stop by booth #9747 to meet the NaturVet team, explore some of their best-selling products and see how the Lopez family is partnering with NaturVet to inspire happier, healthier pets. To learn more about NaturVet and its complete line of vet-formulated supplements, visit About NaturVet NaturVet is a 30-year pioneer and present-day innovator manufacturing high-quality pet products designed to support the health, wellness and quality of life for pets and pet parents. Headquartered in Southern California, NaturVet produces dog, cat and equine supplements including all-in-one vitamins and targeted solutions for calming, digestion, allergy aids, skin and joint support. Formulated by veterinarians and manufactured in-house to ensure quality, NaturVet's products are made with ingredients which are sourced from trusted global suppliers and tested to meet rigorous standards by the National Animal Supplement Council (NASC). For more information, visit View original content to download multimedia: SOURCE NaturVet Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store